SNUG01

DRUG2 trials

Sponsors

Peking University Third Hospital, SineuGene Therapeutics Co., Ltd.

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Early Phase 1

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

Not yet recruitingNCT06645197

Peking University Third HospitalAmyotrophic Lateral Sclerosis (ALS)

Start: 2024-10-16End: 2029-10-15Target: 7Updated: 2024-10-16

Phase 1

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

Not yet recruitingNCT07169175

SineuGene Therapeutics Co., Ltd.Amyotrophic Lateral Sclerosis (ALS)

Start: 2025-12-01End: 2028-09-30Target: 21Updated: 2025-09-11